MarketPulse

GLP-1

7 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.4% Dividend Yield Attracts Income Investors Despite Sector Headwinds

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.
PFEdividend yieldincome investing
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial